Clostridium difficile associated reactive arthritis: Case report and literature review

Anaerobe. 2016 Apr:38:76-80. doi: 10.1016/j.anaerobe.2015.12.011. Epub 2015 Dec 30.

Abstract

Introduction: Extra-gastro-intestinal tract manifestations associated with Clostridium difficile infection (CDI), including reactive arthritis (ReA), are uncommon.

Method: We report a case of ReA associated with a relapse of CDI in a 46-year-old woman. A toxigenic C. difficile strain was isolated from stools and characterized as PCR-ribotype 014/020/077. We conducted a comprehensive literature review of ReA associated with CDI (ReA-CDI). Diagnostic criteria for ReA-CDI were: (i) evidence of aseptic synovitis (confirmed by culture) developing during or immediately after colitis, (ii) presence of a toxigenic C. difficile strain in stool samples, and (iii) absence of other causes of colitis and arthritis.

Results: Forty-nine cases of ReA-CDI (excluding the present report) have already been described since 1976. Of these reports, Mean age of patients was 38 years (SD: 18.5), 46% were male, and 68% had HLA B27 genotype. Sixty-nine percent of patients received a β-lactamin treatment before CDI. ReA-CDI occurred a median 10 days (range 0-55 days) after CDI. Outcome was favorable in 90% of patients and oral non anti-inflammatory drugs were required for 55%.

Conclusion: ReA-CDI remains uncommon. Compared to the general population, it is more likely observed in younger patients with HLA B27-positive genotype.

Keywords: Clostridium difficile; Extra-digestive manifestations; HLA-B27; PCR-ribotype; Reactive arthritis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Arthritis, Reactive / diagnosis
  • Arthritis, Reactive / drug therapy
  • Arthritis, Reactive / etiology*
  • Biomarkers
  • Clostridioides difficile* / classification
  • Clostridioides difficile* / genetics
  • Clostridioides difficile* / isolation & purification
  • Clostridium Infections / complications*
  • Clostridium Infections / drug therapy
  • Clostridium Infections / microbiology*
  • Feces / microbiology
  • Female
  • Humans
  • Inflammation Mediators
  • Middle Aged
  • Prohibitins
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Inflammation Mediators
  • PHB2 protein, human
  • Prohibitins